2021
Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clinical Cancer Research 2021, 27: 6156-6163. PMID: 34465600, PMCID: PMC8595766, DOI: 10.1158/1078-0432.ccr-21-2103.Peer-Reviewed Original ResearchConceptsDisease-free survivalHER2-positive breast cancerShorter disease-free survivalBreast cancerQuantitative immunofluorescenceEarly-stage HER2-positive breast cancerAlpha-smooth muscle actin expressionAlpha-smooth muscle actinProgesterone receptor statusHigh α-SMA expressionDigital Spatial ProfilerΑ-SMA expressionPromising candidate biomarkerCompanion diagnostic testsMuscle actin expressionDigital spatial profilingCohort validationNeoadjuvant lapatinibAdjuvant trastuzumabReceptor statusClinical trialsUnivariate analysisEstrogen receptorMAIN OUTCOMEΑ-SMA
2018
Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens
Rawat RR, Ruderman D, Macklin P, Rimm DL, Agus DB. Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. Npj Breast Cancer 2018, 4: 32. PMID: 30211313, PMCID: PMC6123433, DOI: 10.1038/s41523-018-0084-4.Peer-Reviewed Original ResearchEstrogen receptor statusInvasive ductal carcinomaER statusEstrogen receptorReceptor statusPercent of cellsHormonal therapyDuctal carcinomaImmunohistochemistry stainingHistology patternPathway statusPatient samplesPathway activationPilot studyNuclear featuresDeep neural networksTissue coresNeural networkReceptorsFuture studiesStatusTissue morphologyBiological featuresDeep learning approachCarcinoma
2017
High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence
Wasserman BE, Carvajal-Hausdorf DE, Ho K, Wong W, Wu N, Chu VC, Lai EW, Weidler JM, Bates M, Neumeister V, Rimm DL. High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence. Laboratory Investigation 2017, 97: 1521-1526. PMID: 28892092, PMCID: PMC5711560, DOI: 10.1038/labinvest.2017.93.Peer-Reviewed Original ResearchConceptsInvasive breast cancerBreast cancerQuantitative immunofluorescenceRT-qPCRFormalin-fixed paraffin-embedded tissue blocksRT-qPCR assaysEquivocal categoryReal-time quantitative reverse transcription polymerase chain reactionHER2 receptor statusQuantitative reverse transcription polymerase chain reactionParaffin-embedded tissue blocksReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionIHC/FISHMRNA measurementsAssessment of HER2Low-resource settingsReceptor statusPolymerase chain reactionPathology reportsCT cutsSingle-use cartridgeResource settingsHER2 mRNATissue blocks
2014
Quantitative assessment of miR34a as an independent prognostic marker in breast cancer
Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. British Journal Of Cancer 2014, 112: 61-68. PMID: 25474246, PMCID: PMC4453614, DOI: 10.1038/bjc.2014.573.Peer-Reviewed Original ResearchConceptsDisease-specific survivalBreast cancer cohortPoor disease-specific survivalDisease-specific deathIndependent breast cancer cohortsBreast cancerCancer cohortPoor outcomeCohort 1Multivariate Cox proportional hazards analysisCox proportional hazards analysisNode-positive populationX-tile softwareNode-negative patientsProportional hazards analysisTumor suppressorBreast cancer patientsIndependent prognostic markerExpression of miR34aReceptor statusNode statusPreclinical observationsTumor sizeCancer patientsCohort 2
2012
Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer
Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Research 2012, 14: r124. PMID: 22971274, PMCID: PMC3962029, DOI: 10.1186/bcr3318.Peer-Reviewed Original ResearchConceptsBreast cancer cohortBreast cancerPoor outcomeTumor cellsCancer cohortPoor disease-specific survivalDisease-specific deathDisease-specific survivalBreast cancer patientsIndependent prognostic markerIndependent breast cancer cohortsNon-invasive tumor cellsInvasive tumor cellsReceptor statusNode statusTumor sizeCancer patientsPrognostic markerSignificant associationCohortCancerIsoform expressionPatientsMetastasisOutcomesIn situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.
Vassilakopoulou M, Bordeaux J, Neumeister V, Cheng H, Schalper K, Skarlos D, Pectasides D, Pavlidis N, Koutras A, Linardou H, Razis E, Bobos M, Kotoula V, Rimm D, Fountzilas G, Psyrri A. In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients. Journal Of Clinical Oncology 2012, 30: 573-573. DOI: 10.1200/jco.2012.30.15_suppl.573.Peer-Reviewed Original ResearchBreast cancer patientsMetastatic breast cancer patientsCancer patientsHER2 mRNA levelsHER2 mRNAHistological gradeTrastuzumab-treated metastatic breast cancer patientsMultivariate analysisCox proportional hazards modelHormone receptor statusMetastatic breast cancerKaplan-Meier analysisOverall survival timeMRNA levelsProportional hazards modelHER2 extracellular domainAssessment of HER2Extracellular domainTrastuzumab initiationChemotherapy regimensPrimary endpointReceptor statusTrastuzumab therapyMetastatic cohortTrastuzumab treatment
2007
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis
Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia‐Dąbrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, García‐Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis. International Journal Of Cancer 2007, 121: 1079-1085. PMID: 17487843, DOI: 10.1002/ijc.22812.Peer-Reviewed Original ResearchConceptsBody mass indexPostmenopausal womenEtiologic factorsHER2 levelsPremenopausal womenOdds ratioER alphaBreast cancer hormone receptor statusPopulation-based case-control studyBreast Cancer Hormone ReceptorsHormone receptor statusCase-control studyPopulation-based analysisPathologic characteristicsPR statusReceptor statusMass indexER betaClinical recordsMarker levelsHER2 expressionLarge tumorsBreast cancerReceptor levelsTumor features
2003
Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors
Ocal I, Dolled‐Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003, 97: 1841-1848. PMID: 12673709, DOI: 10.1002/cncr.11335.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorBreast NeoplasmsCohort StudiesErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHepatocyte Growth FactorHumansImmunoenzyme TechniquesKi-67 AntigenLymph NodesLymphatic MetastasisNeoplasm StagingPrognosisProto-Oncogene Proteins c-metReceptor, ErbB-2Receptors, EstrogenReceptors, Fibroblast Growth FactorReceptors, ProgesteroneSurvival RateConceptsLymph node negative breast carcinomaEpidermal growth factor receptorNode-negative breast carcinomaNegative breast carcinomaHER-2Breast carcinomaSet of patientsReceptor tyrosine kinasesGrowth factor receptorReceptor statusTumor sizeWorse outcomesEpidermal growth factor family receptorsProgesterone receptor expression levelsTissue microarray-based studyFamily receptorsHormone receptor statusFactor receptorGroup of patientsIndependent predictive valueExpression levelsReceptor expression levelsUnique staining patternStudy cohortTissue microarray technology